Related Experiment Video

Updated: Nov 27, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.5K

Serum and Glucocorticoid-Inducible Kinase 1 (SGK1) in NSCLC Therapy

Ilaria Guerriero1, Gianni Monaco1, Vincenzo Coppola2,3

  • 1Biogem Institute for Genetic Research Gaetano Salvatore, Ariano Irpino, 83031 Avellino, Italy.

Pharmaceuticals (Basel, Switzerland)
|December 3, 2020
PubMed

Insights

Serum and glucocorticoid-inducible kinase 1 (SGK1) is a promising therapeutic target for non-small cell lung cancer (NSCLC). Inactivating SGK1 may inhibit tumor growth and alter the immune microenvironment, offering new combinatorial treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality globally.
  • Current therapeutic strategies for NSCLC require enhancement, particularly through combinatorial approaches.
  • Serum and glucocorticoid-inducible kinase 1 (SGK1) is frequently overexpressed in NSCLC tumors.

Purpose of the Study:

  • To evaluate serum and glucocorticoid-inducible kinase 1 (SGK1) as a potential therapeutic target for NSCLC.
  • To explore the role of SGK1 in promoting tumor cell survival and modulating the immune microenvironment.
  • To assess the potential of SGK1 inhibition in combinatorial NSCLC therapies.

Main Methods:

  • Review of current literature on SGK1 function in cancer biology and immunology.
  • Analysis of SGK1 expression patterns in NSCLC.
  • Examination of preclinical data on SGK1 inhibitors.

Main Results:

  • SGK1 overexpression in NSCLC is likely stress-induced, creating a therapeutic window.
  • SGK1 promotes cancer cell survival through oncogenic signaling pathways.
  • SGK1 influences immune cell differentiation, promoting pro-tumorigenic phenotypes.

Conclusions:

  • SGK1 inactivation exhibits anti-oncogenic effects on both tumor cells and the immune microenvironment in NSCLC.
  • Targeting SGK1 represents a promising strategy for novel combinatorial therapies in NSCLC.
  • Early-generation SGK1 inhibitors are available, warranting further clinical investigation.
Keywords:
NSCLCSGK1chemotherapyimmunotherapy

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.3K
Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

11.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.4K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.0K